CureVac just 48pc effective

Germany's CureVac yesterday said that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna. The outcome had been expected after poor interim data were released earlier this month. The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.